T-cell activation by treatment of cancer patients with EMD 521873 (Selectikine), an IL-2/anti-DNA fusion protein

Table 1 Treg inhibition capacity

Inhibition of CD4⁺proliferation by Tregs
Dose	Patient	Inhibition (%)
		Day 1	Day 8
0.075	103 1301	99	88
0.075	103 1318	75	48
0.075	102 1213	68	49
0.3	103 1303	97	92
0.3	103 1309	0	0
0.6	103 1310	82	77
0.6	103 1314	0	2
0.6	101 1104	0	0

Capacity of inhibition (%) of CD4⁺ T-cell proliferation induced by CD3⁺/CD28⁺ stimulation by Treg cells, sorted on days 1 and 8 during the second treatment cycle. Samples from 8 randomized patients treated at 0.075, 0.3 and 0.6 mg/kg Selectikine alone were tested.

ISSN: 1479-5876